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Abstract
Background—Although peanut oral immunotherapy (OIT) has been conclusively shown to
cause desensitization, it is currently unknown whether clinical protection persists after stopping
therapy.
Objective—Our primary objective was to determine whether peanut OIT can induce sustained
unresponsiveness following withdrawal of OIT.
Methods—We conducted a pilot clinical trial of peanut OIT at two U.S. centers. Subjects aged
1–16 were recruited and treated for up to five years with peanut OIT. The protocol was modified
over time to permit dose increases to a maximum of 4000 mg peanut protein/day. Blood was
collected at multiple time points. Clinical endpoints were measured with 5000 mg double-blinded,
placebo-controlled food challenges once specific criteria were met.
Results—Of the 39 subjects originally enrolled, 24 completed the protocol and had evaluable
outcomes. 12/24 (50%) successfully passed a challenge one month after stopping OIT and
achieved sustained unresponsiveness. Peanut was added to the diet. At baseline and the time of
challenge, such subjects had smaller skin tests as well as lower IgE levels specific for peanut, Ara
h 1, and Ara h 2, and lower ratios of peanut-specific:total IgE, compared to subjects not passing.
There were no differences in peanut IgG4 levels or functional activity at end-of-study.
Conclusions—This is the first demonstration of sustained unresponsiveness after peanut OIT,
occurring in half of subjects treated up to five years. OIT favorably modified the peanut-specific
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immune response in all subjects completing the protocol. Smaller skin tests and lower allergen-
specific IgE levels were predictive of successful outcome.
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INTRODUCTION
Food allergy is the leading cause of anaphylaxis in children, and in the last 20 years it has
become an increasingly prevalent public health problem with adverse medical, psychosocial
and economic effects. (1–5) This is especially true for peanut allergy, which carries a high
risk of severe reactions (6, 7) and is typically a life-long disorder. (8, 9) Presently, the
standard of care for food allergy is strict dietary allergen elimination and ready access to
emergency medications. Consensus NIH guidelines recommend against the current use of
interventional therapies. (2)
However, recent trials of oral immunotherapy (OIT) have demonstrated progress toward an
active treatment approach for food allergy. (10–15) In a preliminary report from an
uncontrolled pilot study of peanut OIT in children, our group demonstrated that successful
clinical desensitization occurred in 27/29 (93%) of subjects completing more than eight
months of therapy and was associated with relevant mechanistic changes in the peanut-
specific immune response. (13) Subsequently, a randomized placebo-controlled trial
conclusively demonstrated desensitization and immunomodulation, validating the pilot work
and supporting the efficacy of OIT in peanut allergy. (15) Other mechanistic studies have
shown that peanut OIT complexly modifies the IgE and IgG4 responses to the linear
epitopes from the major peanut allergens Ara h 1, 2, and 3, (16) and induces basophil
hyporesponsiveness during treatment. (17) Collectively, these results support the idea that
the immunomodulatory effects of OIT are similar to accepted forms of immunotherapy that
have been proven to be disease-modifying in venom anaphylaxis and respiratory allergy.
(18–20)
Yet only one trial to date has conclusively demonstrated that OIT is disease-modifying,
using egg white powder in egg-allergic subjects. (21) The term “sustained
unresponsiveness” was introduced in this landmark study, describing the ability of a subject
to pass an oral food challenge (OFC) after stopping OIT and successfully introduce a
previously allergenic food into the diet ad libitum. Whereas egg allergy is commonly
outgrown, this is uncommon for peanut allergy, and sustained unresponsiveness to peanut
has not previously been shown.
We sought to determine, in the same peanut-allergic cohort in whom desensitization was
previously reported, (13) whether long-term treatment with OIT would result in sustained
unresponsiveness to peanut, and to identify the clinical and immunologic parameters
associated with this state.
METHODS
Subject Recruitment
This trial was conducted in accordance with the principles of the Declaration of Helsinki.
Ethics approval was obtained through the Institutional Review Boards at Duke University
Medical Center and University of Arkansas for Medical Sciences (UAMS). Written
informed consent was obtained prior to study participation in accordance with each
institution’s ethics guidelines for research in children. Subjects, ages 1 to 16 years, were
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recruited from the allergy and immunology clinics or surrounding community physician
offices at both sites. An interim analysis of this cohort of subjects was previously published;
(13) the end-of-study results of the same clinical trial are presented here.
OIT Protocol
Details of subject selection and the peanut OIT protocol have been previously published,
(13) and are available in the supplemental methods section online. Briefly, OIT was
administered in an open-label fashion to peanut-allergic subjects daily in three phases: initial
day escalation, build-up, and maintenance, which continued until subjects met eligibility for
endpoint assessment as described below. For the duration of the study, subjects strictly
avoided all peanut except for that provided in the dose of their study product.
Clinical Endpoints
Subjects in this study underwent at least three OFCs. The first, which was previously
reported, (13) was an open OFC to 3900 mg of peanut protein conducted shortly after
reaching the maintenance dose. In the current study, qualifying subjects from the previous
report were evaluated with two double-blinded, placebo-controlled food challenges
(DBPCFC) to a total of 5000 mg of peanut protein, performed four weeks apart. Details of
these challenges have been previously published. (15) The first of these challenges (referred
to in the Figures as “Desensitization OFC,” or DOFC) was performed to assess reactivity
while on treatment, and OIT was stopped if this DBPCFC was passed. The next challenge
(referred to in the Figures as “Sustained Unresponsiveness OFC”, or SOFC) was conducted
four weeks after stopping OIT and assessed the primary endpoint called sustained
unresponsiveness, which we operationally defined as the ability to asymptomatically
consume all of the challenge material and then an open oral feeding of one serving (e.g.
8000 – 10,000 mg) of peanut butter afterward on the same day. Subjects passing the SOFC
were classified as treatment successes (TS) and those developing convincing allergic
symptoms during their final SOFC or open feeding were classified as treatment failures
(TF). The criteria for the timing of the assessment of sustained unresponsiveness varied as
the study progressed. The initial protocol called for SOFC once peanut IgE levels were < 2
kU/L. We subsequently amended the protocol to offer SOFCs to subjects with a peanut IgE
< 15 kU/L, peanut SPT < 5 mm, and no peanut-related reactions in the previous six months.
Because of the exploratory nature of this pilot study, if subjects failed the SOFC during
these first two phases of evaluation, they resumed OIT. The final phase of assessment for
sustained unresponsiveness occurred in all remaining subjects, who underwent SOFC at the
completion of five years of OIT, regardless of their immune parameters. TS were advised to
incorporate peanut into the diet ad libitum at least several days per week. The day after the
final SOFC, TF were restarted on a predetermined amount of a peanut-containing food daily
and are being followed.
Clinical and Mechanistic Studies
Skin prick tests were performed in standard clinical fashion throughout the study.
Mechanistic studies investigating serological and cellular responses to OIT, and utilizing
purified peanut reagents, were performed as previously described (13) on the subjects
enrolled at one of the study sites, due to the availability of specimens there. Additional
details about these assays may be found in the supplementary material online.
Follow-up
A ten-question telephone survey was developed to assess post-OIT dietary habits, safety,
and beliefs/attitudes after study completion. Contact was attempted with all subjects who
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had an evaluable outcome. The questionnaire is available in the supplementary material
online.
Statistical Methods
We computed averages, variances, frequencies, proportions, and graphical displays for all
clinical and immunologic variables (GraphPad, La Jolla, CA). We used Wilcoxon rank sum
and Mann-Whitney tests for between-group comparisons of immunologic and FAB data,
respectively, at single time points. Kruskal-Wallis and Fisher’s Exact tests were used for
between-group comparisons of questionnaire data. For longitudinal analyses, we used
Bonferroni-corrected nonparametric two-way repeated measures ANOVA or simple linear
regression. The area under the receiver operating curve was calculated to determine
between-group predictors. P-values < 0.05 were considered significant.
RESULTS
Subject demographics
39 subjects were originally enrolled in the trial, and ultimately 24 (62%) had an evaluable
outcome with respect to sustained unresponsiveness (Figure 1). 6/39 (15%) of enrolled
subjects withdrew for allergic side effects; the remaining nine were for personal or other
reasons. Clinical and demographic characteristics of the 24 evaluated subjects were no
different than those of the subjects withdrawing (not shown). As previously noted, subjects
in this study were not evaluated for sustained unresponsiveness at the same time interval,
with a mean (SD) length of treatment of 1453 (663) days.
Half of finishing subjects achieved sustained unresponsiveness
Twelve TS subjects (50% per protocol; or 31% by intent-to-treat) consumed 5000 mg of
peanut protein and an open oral feeding of peanut butter without symptoms four weeks after
stopping OIT and were considered to have achieved sustained unresponsiveness (Figure 2).
Among TF, the median (range) amount of peanut protein ingested cumulatively prior to the
development of symptoms was 3750 (1500–5000) mg, equivalent to approximately 12
peanuts on average.
Sustained unresponsiveness was inversely associated with skin test reactivity at baseline
and end-of-study
At baseline, TS had smaller skin tests than TF (median 9 mm versus 14 mm, respectively;
p=0.02) (Figure 3A). During treatment in all subjects, OIT suppressed mast cell
responsiveness, as demonstrated by a reduction in mean wheal diameter in skin prick tests
obtained at baseline and at the time of the DOFC. This suppression persisted in TS upon
discontinuation of OIT, whereas in TF, wheal diameters returned to near-baseline levels
(Figure 3B).
Intensity of allergic priming was inversely related to sustained unresponsiveness
Compared to TF at baseline and at every subsequent time point measured, TS had lower
median IgE levels specific for peanut, Ara h 1, and Ara h 2 (Figures 4A and 4B). The total
amount of IgE was not different between groups (not shown). Importantly, all subjects on
OIT experienced a longitudinal reduction to below baseline levels for some (peanut, Ara h 1,
2, 3) but not all (Ara h 8, 9) allergen-specific IgE. (Figure 4C) All subjects experienced a
reduction in the ratio of peanut-specific to total IgE (Figure 4D), and this ratio was lower at
baseline and at end-of-study in TS as compared to TF (Figure 4E).
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Sustained unresponsiveness was not associated with the amount or inhibitory capacity of
peanut-specific IgG
Peanut-specific IgG, including IgG4, increased in all subjects (Figure 5A). During the first
year, a striking increase occurred in the total amount of peanut-specific IgG of subtypes
other than IgG4. This production peaked at about 12 months of therapy and then dropped,
reaching a steady-state at around 18 months; in contrast, IgG4 production steadily increased
over time. The amount of peanut-specific IgG4 was not associated with clinical outcome at
baseline or at end-of-study (Figure 5B). The ratio of peanut-specific IgE to IgG4 steadily
declined over the course of therapy (Figure 5C), and was significantly different between
groups at baseline and at end-of-study (Figure 5D). Figure 6A shows the inhibitory capacity
of IgG in a subset (N=14) of subjects, demonstrating considerable variance but an overall
increase in the inhibitory activity of subjects’ sera over time [slope −0.49 (95%CI, −0.78 to
−0.19), p=0.002]. Unexpectedly, there was a trend towards TS sera having lower inhibitory
function than TF, which was statistically significant at 12 months but not at time of
challenge (Figure 6B).
Sustained unresponsiveness was not associated with the number of regulatory T cells at
SOFC
There were no between-group differences in the proportion of CD4+CD25+FOXP3+ T cells
at end-of-study, in a subset of subjects for whom sufficient cells were available (Figure E1).
Predictors of sustained unresponsiveness
We determined with ROC analysis whether readily available parameters could discriminate
between TS and TF at baseline and end-of-study. At baseline, the strongest predictor was the
ratio of peanut-specific:total IgE (Figure E2) [AUC=0.96; p=0.005], whereas at end-of-
study, it was Ara h 2-specific IgE (Figure E3) [AUC=0.9; p=0.003]. Notably, the second-
best predictor in both baseline and end-of-study parameters was peanut-specific IgE. Peanut-
specific IgG4 had no discriminatory power at either time point.
Successes consume peanut without symptoms after stopping OIT
Questionnaire response was 87.5% (n=21). The median (range) time to follow-up after the
SOFC in the TF group was 12 (3–36) months and 40 (3–56) months among TS. None of TS
reported allergic reactions associated with peanut exposure, whereas three (14%) TF
reported mild peanut reactions, none of which required epinephrine or a physician visit. TS
incorporated a median 555 (0–4000) mg/day of peanut protein into the diet on average three
(0–7) days/week. This was less frequent compared to TF, who incorporated a median 895
(330–4000) mg/day, seven (5–7) days/week [p=0.0003 for frequency comparison]. The
longest median interval in days between peanut exposures was greater in TS (14, range 2 to
>365) than in TF (2, 0–7) [p=0.004]. One of the TS stopped taking peanut in the diet due to
personal, not medical, considerations; and over the subsequent year, we observed significant
increases in his skin test size (0.5 mm to 16 mm) and in vitro IgE levels (3.56 kU/L to 11.5).
We have advised him to continue peanut avoidance. Fifty-seven percent of parents
encountered some difficulty in getting their child to willingly consume peanut in their diets,
with nineteen percent each reporting difficulty “about half of the time,” and “every time;”
these frequencies were not different between TS and TF. All surveyed families reported
satisfaction with their decision to participate in the study; their post-study narrative
comments appear in Table E1.
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Here we report on the end-of-study results of our initial pilot trial of peanut OIT, providing
an update from our previously published interim report. (13) After a maximum of five years
and 4000 mg/day of OIT, all subjects completing the study successfully ingested 5000 mg of
peanut protein without symptoms during the DOFC and were considered desensitized. Fifty
percent of these individuals successfully repeated this challenge one month after stopping
OIT and demonstrated sustained unresponsiveness. This trial lacked the placebo control
required for definitive proof, but based on natural history studies, (8, 9, 22) it is highly
unlikely that half of the study population would have outgrown peanut allergy during this
study period. Thus these data represent the first descriptions of a lasting state of sustained
unresponsiveness among peanut-allergic children treated with OIT and serve as proof of
concept that such an outcome is possible. We advised successful subjects to incorporate
peanut into their diet on a regular basis without restriction as if they were no longer allergic.
A relapse appears likely in the one successful subject described above who could not do this.
However, despite reporting that it was frequently difficult, all of the other TS now regularly
do consume relatively small amounts of peanut, to which they were previously highly
allergic. It is not known at present whether this clinical change is permanent, but notably we
have a median of over 40 months’ follow-up. The ability of OIT trial participants, even
those classified as successes, to reintroduce allergen into the diet long term after study
completion has been questioned (23), and it appears this may be necessary to prevent relapse
in some subjects, as we observed. Although we report a substantially higher proportion of
dietary adherence than Keet et al. over a longer period of follow-up, we share the concern
that a need for ongoing regular oral exposure during and after therapy may be a potential
limitation of this approach and an area that requires much more study.
Interestingly, among TF, a median cumulative 3750 mg was required to elicit symptoms
during the SOFC. This eliciting dose is several orders of magnitude greater than at baseline,
when, although not formally challenged, all subjects had clinical reactions prior to reaching
the 50 mg dose on the initial escalation day. (13) Thus, even in participants not achieving
the primary outcome, OIT still induced a state of altered reactivity between peanut allergy
and sustained unresponsiveness. One possible explanation is that among TF, who all passed
the DOFC and were considered desensitized, the protective effects of OIT began to subside
during the four weeks off of therapy. As was seen in another short peanut OIT trial, (14)
clinical reactivity in the post-treatment OFC was linked to the return of peanut-induced mast
cell activation. Other studies of egg, milk, and peanut OIT have also shown that the clinical
desensitization effect was transient, in some cases within one or two weeks after
discontinuing OIT. (11, 14, 25) However, as in this study, the reaction threshold in all
subjects from both of these studies remained well above their baseline. Of note, subjects in
the current study were treated for up to five years, the longest trial of peanut OIT published
to date, and far longer than the studies cited above. This could help explain the overall
success rate and also the high eliciting dose during the SOFC among TF. Based on other
OIT studies and the broad experience with subcutaneous allergen immunotherapy, it is likely
that the length of treatment (24, 26) and the antigen dose (25) influence the durability of the
treatment effect. However, the factors governing the change in clinical state remain poorly
understood and require further study. These observations also underscore the importance of
study design with respect to how and when the primary outcome is defined and measured.
Mechanistically, we looked for evidence of increased peanut-specific regulatory T cells in
TS but these cell frequencies did not differ by outcome. We did observe that an overall
increase in peanut-specific IgG4 during OIT was accompanied by a consistent parallel
decrease in allergen-IgE binding to B cells. Both raised specific IgG4 levels and increased
serum inhibitory activity were paradoxically observed in TF compared to TS. One
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explanation could be the use of pooled indicator serum rather than participants’ autologous
baseline serum for the IgE-FAB inhibition assay. The availability of serum was insufficient
to allow for this alternative experimental design. However, we consider this explanation
unlikely since in previous studies use of indicator or baseline autologous serum have yielded
comparable results (27), and the data are consistent with previous studies of venom
immunotherapy where these markers bore no relationship to clinical outcome. (28) During
peanut OIT, in contrast to immunotherapy for respiratory allergy, (29) it is possible that IgE
and/or mast cell suppression drives desensitization rather than elevated IgG4 and IgE-FAB
inhibition. These findings warrant further study.
We observed a number of other interesting findings about the antibody response during OIT.
In TF, the peanut-specific IgE level amplified over the first six months of therapy, as did
peanut-IgG responses (including IgG4 and other isotypes). Because TF started OIT with
higher baseline peanut-IgE levels than TS, this amplification could be due to IgE-mediated
facilitated antigen presentation (IgE-FAP), which has been shown to drive pathological T-
cell responses in peanut-allergic but not control subjects. (30) If true, this could explain why
subjects with lower IgE levels at baseline have better outcomes following OIT. The possible
role of IgE-FAP in determining the response to OIT deserves further study. An important
aspect of the study is that in all subjects, whether initially amplified or not, peanut-specific
IgE was reduced to below the baseline level after a median 12 months of OIT; and this
occurred proportionally in both groups to the same degree and independent of outcome (not
shown). TS had lower IgE levels to peanut, Ara h 1 and 2 at baseline and end-of-study,
compared to TF, a trend observed in numerous other natural history and OIT studies. The
change over time in total peanut-specific IgE was paralleled by similar changes in IgE
specific for Ara h 1 and 2, but not Ara h 3, 8, and 9, suggesting that IgE binding to these
major allergens is an important target during OIT. Although we can detect Ara h 1 and Ara h
2 in the peanut flour used in this study (data not shown), in general there is little known
about the relationship between major allergen dose and outcomes. This is a knowledge gap
requiring further investigation.
Several single-center uncontrolled studies have previously reported on the development of
sustained unresponsiveness following egg (11, 26) and milk (11, 25) OIT, but none with
peanut. The only report of sustained unresponsiveness from a placebo-controlled trial of
food OIT was recently published in a landmark egg OIT paper from the Consortium of Food
Allergy Research. (21). This large multicenter study by Burks et al demonstrated that
sustained unresponsiveness occurred in 27.5% of subjects actively treated for 22 months,
compared with none in the placebo group. Successes consumed ten grams of egg-white
powder and one whole egg without symptoms during a challenge four to six weeks after
stopping OIT. Consistent with our observations, sustained unresponsiveness was associated
with significantly smaller skin prick tests at the time of the SOFC, linking sustained mast
cell suppression to a successful outcome. Importantly, no OIT study to date, including the
current one, has followed a placebo control group through to the end-of-study.
Nonconsecutive enrollment, substantial subject withdrawal, and the lack of a control group
are limitations in this trial, but they are common to exploratory pilot studies that carry
significant and unknown risks upon inception. It is worth noting that, although there are
currently many trials of peanut OIT around the world, this trial began in 2003 and was one
of the first. Recruitment and retention were problematic and safety concerns were
paramount.
In summary, we demonstrate for the first time that sustained unresponsiveness developed in
half of peanut-allergic subjects able to complete treatment with years of OIT. Although it is
not proven that this was due to OIT, it is unlikely to have occurred spontaneously. This
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change in reactivity has allowed the treatment successes to resume a diet unrestricted of
peanut. Although OIT was immunomodulatory in all participants, lower peanut-IgE levels at
baseline and smaller skin tests at end of study predicted successful outcomes. Larger trials
with rigorous designs are warranted to further investigate the long-term effects of OIT in
peanut-allergic subjects.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Half of peanut-allergic subjects completing this pilot study of peanut OIT
consumed 5000 mg of peanut protein and an open oral feeding of peanut butter
one month after stopping treatment.
• It is not known if this change is permanent, but most of these subjects are
consuming peanuts in their diet.
• These subjects started and ended the study with less peanut- and Ara h 1- and
Ara h 2- specific IgE, smaller skin tests, lower peanut-specific:total IgE ratios,
and similar IgG4 levels compared to those unable to pass the final challenge.
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Conduct of the study.
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Food challenge results. Shown are the cumulative amounts of protein successfully ingested
prior to the onset of symptoms in TS (blue) and TF (red) circles. Each circle represents one
subject.
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Skin prick test results. (A) Average mean wheal diameters at baseline are shown, by
outcome. (B) Mean wheal diameters over time, by outcome. Lines represent median values.
*p<0.05; **p<0.01; ***p<0.001
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Peanut- and component-specific serum IgE during OIT. Longitudinal peanut- (A), and Ara h
1-, and Ara h 2-specific (B) IgE are shown for individual subjects by outcome, and for all
components in all subjects (C). Peanut-specific IgE to total IgE ratio is shown for all
subjects (D) and for individual subjects by outcome (E). All point estimates are medians,
with interquartile range (C). *p<0.05; **p<0.01; ***p<0.001.
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Peanut-specific serum IgG, IgG4, and IgE/IgG4 ratios during OIT. Median values for all
subjects’ longitudinal peanut-specific IgG and IgG4, and Ara h 2-specific IgG4 are shown
(A). Peanut-specific IgG4 (B) are shown for individual by outcome. Peanut-specific IgE/
IgG4 ratios are shown for all subjects (C), and by outcome (D). Lines representing medians.
*p<0.05; **p<0.01
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Serum from subjects on peanut OIT inhibits facilitated antigen binding (FAB). FAB data are
shown for all individual subjects in grey, with mean linear regression slope coefficient
(black line) and 95%CI (hatched line)(A). FAB by outcome, with lines representing medians
(B). ** p<0.01.
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